Cocrystal Pharma, Inc. COCP
1.17
0.02
1.74%
as of 25 Sep
- Market cap
- $22.2M
- P/E
- 0.0×
Follow COCP
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (311.68%) | (154.62%) | (111.40%) | (94.94%) |
+8 more TTM periods Free account |
|
| (151.10%) | (97.64%) | (76.23%) | (72.50%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(1,442.38%) | (232.89%) | (146.77%) | (131.26%) | |
Average Days of Receivables |
202.14 | 156.22 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.58) | (0.55) | (0.73) | (0.88) | |
Free Cash Flow |
(7.95) | (7.59) | (8.20) | (9.63) | |
Capital Expenditures |
— | — | (0.01) | (0.01) | |
Piotroski F-Score |
4.00 | 3.00 | — | — | |
| Other line items | |||||
Cash ROIC |
(241.91%) | (85.55%) | (60.99%) | (62.15%) | |
Accounts Receivable Turnover |
1.12 | 1.61 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
457.94% | 284.93% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
327.61% | 235.83% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
21.07% | 15.30% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.80 | 0.86 | 0.93 | 0.99 | |
Depreciation/Fixed assets |
5.29 | 4.48 | 4.04 | 3.64 | |
Capex/Depreciation |
0.00 | 0.00 | (0.03) | (0.03) | |
Revenue per Share |
0.10 | 0.13 | 0.00 | 0.00 | |
Operating CF per Share |
(0.58) | (0.55) | (0.73) | (0.87) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(747.78%) | (496.57%) | 0.00% | 0.00% |
Columns are period end dates